A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Stopped The sponsor decided not to continue the study based on the overall company strategy in AML.

Conditions

• Myelodysplastic Syndromes (MDS)

Interventions

• COMBINATION_PRODUCT: Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine

Sponsor

Sumitomo Pharma America, Inc.